. Elevation of the serum CPK activity in rabbits (New Zealand strain, males, 2 to 3 kg) injected with chlorpromazine. Creatine phosphokinase activity (2) is expressed in international units (I.U.) per liter. The CPK activity before injection was determined on each of the 3 days immediately before treatment, and CPK activity after injection was obtained 18 hours after treatment. All injections were given intramuscularly. One group received 0.5 ml of a commercial preparation of chlorpromazine hydrochloride (Thorazine, 25 mg/mI); another received 0.5 ml of sodium chloride (U.S.P., 9 mg/ml); and a third received 0.5 ml of the aqueous vehicle which is used for the intramuscular injection of chlorpromazine (ascorbic acid, 2 mg/ml; sodium bisulfite, I mg/ml; sodium sulfite, 1 mg/ml; sodium chloride, 1 mg/ml; benzyl alcohol, 2 percent); Cpz, chlorpromazine.
Rab-CPK activ- ( creased activity. He stated that neither physical exertion nor the administration of phenothiazines was related to the increased enzyme activity.
We assayed serums from 58 patients (successive admissions) for creatine kinase activity (2) (normal values, 12 to 58 I.U./liter). Five of the 25 acutely psychotic patients had CPK levels higher than 60 I.U/liter; three of the five had received intramuscular chlorpromazine within 72 hours before the assay. Of the 33 who were not acutely psychotic, two had CPK levels higher than 60 I.U./liter, although neither had received the drug intramuscularly. Of the 51 patients with CPK levels below 60, -only one had received,the drug in the preceding 72 hours. None of the patients had received intramuscular injections of any other drugs.
These observations suggesited that intramuscular injection of chlorpromazine might cause the elevated CPK activity in serum. We, therefore, did the following study. Six rabbits received the drug intramuscularly, three received physiolbgic saline intramuscularly, and three received an intramuscular injection of the vehicle of a commercial chlorpromazine preparation. All CPK activity was shown to be of the muscle type by gel electrophoresis (3).
After the injection was given, the mean CPK activity of the group injected with chlorpromazine was significantly greater than the means for the other groups and the means of all groups before injection (Table 1 ).
There were no significant differences between the means of all groups before injection, or between the means of the saline group before and after injection. The increase in CPK activity after injection was attributed to the intramuscular effect of chlorpromazine because there was no significant difference between the means of the saline and vehicle groups after injection (P > .15) even though there was a small but significant increase in the mean of the vehicle group after injeotion. The mean CPK activity of the chlorpromazine group returned to normal (84 ± 13) in 6 days, and this group was again given chlorpromazine (0.5 ml intramuscularly). The mean activity obtained as soon as 18 hours later (967 + 163) was again greater (P > .001) than the activity before injection.
This increase in CPK activity after injection of chlorpromazine is therefore due principally to the drug. Patients have been reported to have elevatted serum CPK concentrations after exercise (4) and after needling for electromyography (5 It may be possible to distinguish between the two causes of increased activity of CPK under consideration. I have noted that the increases in CPK activity in humans due to intramuscular Thorazine tend to last 2 to 4 days, whereas the increases which occur presumably as part of the acute psychotic process tend to last 10 to 14 days; in one case increased activity persisted 51 days. We have found no increases in serum aspartate aminotransferase (glutamic oxalacetic transaminase) and serum lactate dehydrogenase activity associated with the increased CPK activity after intramuscular injection of Thorazine which is the same as in the acute psychoses (1). In any event, investigators of the serum enzyme changes in acute psychoses should obtain serum samples before giving intramuscular injections.
The small proportion of acutely psychotic patients in which Warnock and Ellman found increased CPK activity, 5 of 25, of which three may have been due to intramuscular injections, is significantly lower than that I have found in three studies: 14 of 16 in a study at the National Institutes of Health (1) , 24 of 39 in a blind study at the Massachusetts Mental Health Center (5), and 24 of 37 in Chicago (4). It is also less than that reported by Schiavone and Kaldor and by Bengzon (2) . There are at least four possible factors to consider for this difference: (i) the patients reported by Warnock and ElIman were mainly chronically psychotic patients experiencing an acute exacerbation of their illness, not the acute-type patient I have described; (ii) there had been a long delay between the onset of the acute psychosis and the time the blood samples were obtained; (iii) not all unequivocally acutely psychotic patients (unpublished data) from whom blood samples are taken within a few days of the onset of their psychosis and studied longitudinally thereafter will have markedly increased CPK activity; this may signify that there are two classes of acute psychotics with regard to the property of an increase in serum CPK activity accompanying the psychotic episode; the distribution of these groups may be uneven in studies with few subjects as it appears to have been in the NIH study (biased toward CPK releasers) and perhaps in the group of patients reported by Warnock and Ellman (biased toward CPK nonreleasers); (iv) the possibility that the increased CPK activity is an artifact bearing no relation to the psychotic process and caused by some other confounding influence not yet discovered and not present in Warnock's and Ellman's patients.
With regard to the rabbit studies reported by Warnock and Ellman, the dose of Thorazine given-4.2 to 6.2 mg/kg-is five to ten times the usual human intramuscular dose; and the volume injected (0.5 ml) into a small rabbit muscle is probably 15 to 30 times as large as a 1-to 2-ml injection into a human muscle. I have given rats chlorpromazine in saline as well as Thorazine in intramuscular doses from 0.5 to 10 mg/kg, in a volume of 0.05 ml, and killed them from 4 to 16 hours later; I found slight change in serum CPK activity. Part of the discrepancy may be due to species variation and part to significant variation in the local trauma from the injection. The release of CPK from rat muscle does not appear to be a pharmacologic property of chlorpromazine, for I have observed no increase in CPK activity in rats given chlorpromazine intraperitoneally or from rat muscle incubated with chlorpromazine in vitro.
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